Jacqueline M. Cohen

Jacqueline M. Cohen

Auto-generated profile, based on publicly available information

Jacqueline M. Cohen

Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
KHKrista F. Huybrechts
Krista F. Huybrechts
SHSonia Hernández-Díaz
Sonia Hernández-Díaz
EPElisabetta Patorno
Elisabetta Patorno
RDRishi J. Desai
Rishi J. Desai
HMHelen Mogun
Helen Mogun
BBBrian T. Bateman
Brian T. Bateman
Exposure to antipsychotics (APs) during pregnancy is increasingly common. Most newer atypical drugs are less likely to affect fertility than the older typical APs. This unimpaired fecundity combined with deinstitutionalization of patients with psychiatric illness and more widespread off-label use of these drugs have resulted in a doubling in the use of APs during pregnancy in the last decade.1,2

8 June 2017 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
EPElisabetta Patorno
Elisabetta Patorno
KHKrista F. Huybrechts
Krista F. Huybrechts
BBBrian T. Bateman
Brian T. Bateman
JCJacqueline M. Cohen
Jacqueline M. Cohen
RDRishi J. Desai
Rishi J. Desai
SHSonia Hernandez-Diaz
Sonia Hernandez-Diaz
There has been concern that exposure to lithium early in pregnancy may be associated with a marked increase in the risk of Ebstein’s anomaly (a right ventricular outflow tract obstruction defect) in infants and overall congenital cardiac defects, but data are conflicting and limited. We conducted a cohort study involving 1,325,563 pregnancies in women who were enrolled in Medicaid and who delivered a live-born infant between 2000 and 2010. We examined the risk of cardiac malformations among infants exposed to lithium during the first trimester as compared with unexposed infants and, in secondary analyses, with infants exposed to another commonly used mood stabilizer, lamotrigine. Risk ratios and 95% confidence intervals were estimated with control for psychiatric and medical conditions, medications, and other potential confounders. Cardiac malformations were present in 16 of the 663 infants exposed to lithium (2.41%), 15,251 of the 1,322,955 nonexposed infants (1.15%), and 27 of the 1945 infants exposed to lamotrigine (1.39%). The adjusted risk ratio for cardiac malformations among infants exposed to lithium as compared with unexposed infants was 1.65 (95% confidence interval [CI], 1.02 to 2.68). The risk ratio was 1.11 (95% CI, 0.46 to 2.64) for a daily dose of 600 mg or less, 1.60 (95% CI, 0.67 to 3.80) for 601 to 900 mg, and 3.22 (95% CI, 1.47 to 7.02) for more than 900 mg. The prevalence of right ventricular outflow tract obstruction defects was 0.60% among lithium-exposed infants versus 0.18% among unexposed infants (adjusted risk ratio, 2.66; 95% CI, 1.00 to 7.06). Results were similar when lamotrigine-exposed infants were used as the reference group. Maternal use of lithium during the first trimester was associated with an increased risk of cardiac malformations, including Ebstein’s anomaly; the magnitude of this effect was smaller than had been previously postulated. (Funded by the National Institute of Mental Health.)

22 July 2019 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
SMSarah C. MacDonald
Sarah C. MacDonald
JCJacqueline M. Cohen
Jacqueline M. Cohen
Alice PanchaudAlice Panchaud
Alice Panchaud
TMThomas F. McElrath
Thomas F. McElrath
KHKrista F. Huybrechts
Krista F. Huybrechts
SHSonia Hernández‐Díaz
Sonia Hernández‐Díaz

23 January 2018 in Neurology
Verified
Journal Article
Closed access
PDF file
SHSonia Hernandez-Diaz
Sonia Hernandez-Diaz
KHKrista F. Huybrechts
Krista F. Huybrechts
RDRishi J. Desai
Rishi J. Desai
JCJacqueline M. Cohen
Jacqueline M. Cohen
HMHelen Mogun
Helen Mogun
EPElisabetta Patorno
Elisabetta Patorno
Objective To assess the relative risk of oral clefts associated with maternal use of high and low doses of topiramate during the first trimester for epilepsy and nonepilepsy indications. Methods This population-based study nested in the US 2000–2010 Medicaid Analytic eXtract included a cohort of 1,360,101 pregnant women with a live-born infant enrolled in Medicaid from 3 months before conception through 1 month after delivery. Oral clefts were defined as the presence of a recorded diagnosis in claims during the first 90 days after birth. Women with a topiramate dispensing during the first trimester were compared with those without any dispensing and with an active reference group of women with a lamotrigine dispensing during the first trimester. Risk ratios (RRs) were estimated with generalized linear models with fine stratification on the propensity score of treatment to control for potential confounders. Stratified analyses by indication of use and dose were conducted. Results The risk of oral clefts at birth was 4.1 per 1,000 in the 2,425 infants born to women exposed to topiramate compared with 1.1 per 1,000 in the unexposed group (RR 2.90, 95% confidence interval [CI] 1.56–5.40). The RR among women with epilepsy was 8.30 (95% CI 2.65–26.07); among women with other indications such as bipolar disorder, it was 1.45 (95% CI 0.54–3.86). The median daily dose for the first prescription filled during the first trimester was 200 mg for women with epilepsy and 100 mg for women without epilepsy. For topiramate monotherapy, the RR for oral clefts associated with doses ≤100 mg was 1.64 (95% CI 0.53–5.07) and for doses >100 mg it was 5.16 (95% CI 1.94–13.73). Results were similar when lamotrigine was used as a reference group. Conclusion The increased risk of oral clefts associated with use of topiramate early in pregnancy was more pronounced in women with epilepsy, who used higher doses.

15 December 2014 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
ARA. Rabinovich
A. Rabinovich
JCJ. M. Cohen
J. M. Cohen
MCMary Cushman
Mary Cushman
PWP. S. Wells
P. S. Wells
MRM. A. Rodger
M. A. Rodger
SKS. R. Kahn
S. R. Kahn
Background Post‐thrombotic syndrome (PTS) is a frequent chronic complication of deep vein thrombosis (DVT). Objective In the BioSOX study, we investigated whether inflammation markers predict the risk of PTS after DVT. Methods We measured C‐reactive protein (CRP), ICAM‐1, interleukin (IL)‐6, and IL‐10, at baseline, and 1 month and 6 months after a first proximal DVT, among 803 participants in the SOX trial. Participants were prospectively followed for 24 months for development of PTS. Results Median CRP levels at 1 month, ICAM‐1 levels at baseline, 1 month and 6 months, IL‐6 levels at 1 month and 6 months and IL‐10 levels at 6 months were higher in patients who developed PTS than in those who did not. Multivariable regression with the median as a cutoff showed risk ratios (RRs) for PTS of 1.23 (95% confidence interval [CI] 1.05–1.45) and 1.25 (95% CI 1.05–1.48) for ICAM‐1 at 1 month and 6 months, respectively, and 1.27 (95% CI 1.07–1.51) for IL‐10 at 6 months. Quartile‐based analysis demonstrated a dose–response association between ICAM‐1 and PTS. ICAM‐1 and IL‐10 were also associated with PTS severity. Analysis of biomarker trajectories after DVT demonstrated an association between the highest‐trajectory group of ICAM‐1 and PTS. Conclusions In this prospective study, ICAM‐1 over time was most consistently associated with the risk of PTS. Further study is required to confirm these findings and assess their potential clinical relevance.

16 July 2013 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
SKSusan R Kahn
Susan R Kahn
DMDavid R Morrison
David R Morrison
JCJacqueline M Cohen
Jacqueline M Cohen
JEJessica Emed
Jessica Emed
VTVicky Tagalakis
Vicky Tagalakis
WGWilliam Geerts
William Geerts